Skip to main content

Table 3 Base case results (95% Credible Intervals) for cohort of 3200 women. All costs are in 2019 United States Dollars (US$)

From: Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border: a cost-effectiveness analysis

Strategy Cost Incremental cost Infections Infections averted ICER
Vaccine only $ 19,639 (11,202–30,258) base 22 (17–27) base base
TDF after HBeAg test $ 30,254 (21172–41,413) $ 10,615 (7539–13,952) 11 (9–14) 11 (7–14) $ 980 (689–1454)
TDF after PCR $ 31,715 (22264–43,001) dominated 11 (9–16) dominated dominated
HBIG & TDF after PCR $ 34,791 (24915–46,417) dominated 11 (9–15) dominated dominated
TDF after RDT $ 39,845 (28439–52,958) $ 9591 (4533–16,108) 7 (5–10) 4 (3–5) $ 2489 (1267–4410)
HBIG after RDT $ 42,275 (29,145–58,319) dominated 17 (12–22) dominated dominated
  1. DNA Deoxyribonucleic acid, HBeAg hepatitis B envelope antigen, HBV hepatitis B virus, ICER incremental cost-effectiveness ratio, RDT Rapid diagnostic test, TDF Tenofovir Disoproxil Fumarate